BioHarvest Sciences Inc. Common Stock (BHST) 株式分析

企業概要

BioHarvest Sciences Inc. operates as a biotechnology entity headquartered in Israel and the United States, utilizing a botanical synthesis platform technology to cultivate plant cells with elevated concentrations of active ingredients for use in nutraceuticals and pharmaceuticals. The firm is classified within the Consumer Defensive sector and specifically functions in the Packaged Foods industry, positioning its products in markets where consumer demand for essential goods remains relatively stable despite economic fluctuations. The company's scale is reflected in a market capitalization of $97.02M and an annual revenue of $34.51M, supported by an operational workforce of 89 employees. These valuation and revenue figures indicate that BioHarvest Sciences Inc. functions as a small-cap entity with a relatively modest revenue base, suggesting a business model currently focused on scaling production capabilities and market penetration rather than established large-scale market dominance.

財務健全性

The company reported a trailing twelve-month revenue of $34.51M, yet this revenue generated a net income of $-11,135,000 and an EBITDA of $-5,111,000, revealing a significant divergence between top-line growth and profitability. The substantial gap between the $34.51M revenue and the negative net income highlights a cost structure where operating expenses and costs of goods sold exceed gross margins, resulting in an overall loss. Free cash flow stands at $-10,782,250, which indicates that the company is currently burning cash, implying limited immediate financial flexibility to fund operations without external capital infusion. Profitability analysis shows a gross margin of 59.3%, suggesting strong pricing power or low cost of goods, but this is offset by an operating margin of -12.4% and a profit margin of -32.3%, indicating high overhead costs or research and development expenditures are eroding bottom-line earnings. The balance sheet holds $23.04M in cash against $14.10M in debt, resulting in a debt-to-equity ratio of 55.42%, which presents a mixed picture of liquidity coverage but elevated leverage relative to equity. Despite having sufficient cash to cover debt principal, the high debt-to-equity ratio suggests a leveraged balance sheet that relies on future cash generation to service obligations. Liquidity is robust with a current ratio of 3.97, indicating the company possesses nearly four times the current assets necessary to meet its short-term liabilities. Return on equity is recorded at -83.2% and return on assets at -9.6%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.

バリュエーション評価

Valuation metrics for BioHarvest Sciences Inc. are distorted by its lack of profitability, as the P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is calculated at -107.00. The existence of a negative forward P/E implies that the market is pricing in expectations of continued losses or that earnings are not yet sufficient to support a traditional earnings multiple, highlighting the speculative nature of the investment based on future growth potential rather than current profitability. The price-to-book ratio stands at 3.81, indicating that the stock is trading at a significant premium of approximately 281% over its net asset value, which suggests the market values the company's intangible assets, such as its botanical synthesis platform technology, higher than the book value of its tangible assets. Alternative valuation metrics provide further context, with a price-to-sales ratio of 2.81 and an EV/EBITDA of -17.23; these figures suggest the market is willing to pay a multiple of nearly three times sales, despite the negative enterprise value-to-earnings multiple caused by the EBITDA loss. Price action over the past year has seen the stock fluctuate between a 52-week low of $4.10 and a 52-week high of $12.80, with the current market price situated somewhere within this range, reflecting the volatility typical of small-cap biotechnology firms. The beta of 1.40 indicates that the stock exhibits 40% higher volatility than the broader market, meaning price movements are amplified relative to general market shifts, a characteristic often observed in emerging biotechnology sectors awaiting clinical or commercial breakthroughs.

Growth & Income

Revenue growth for the trailing twelve months stands at 24.6%, demonstrating a strong top-line expansion trajectory, whereas earnings growth is listed as N/A due to the company's persistent net losses. This divergence implies that while the company is successfully scaling its sales volume, the growth rate is not yet translating into proportional profit improvement, a common challenge for biotechnology companies in the early commercialization phases that are heavy on investment. The company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are retained within the business to fund ongoing research, development, and capital expenditures rather than being paid out as income. Consequently, the overall growth and income profile is characterized by aggressive reinvestment of capital to drive future revenue expansion, with investors foregoing current income in exchange for potential future value creation contingent on the successful commercialization of their botanical synthesis technologies.